The Expert Angle

Medlior is a well-known and trusted industry leader.

Our team is dedicated to delivering high-quality research that provides a solid basis for informed decision-making.

Medlior’s Expert Angle offers the inside track on new studies, industry hot topics, and what you need to know in the fast-paced world of clinical research, all from the point of view of the Medlior team of experts. From the latest topics and trends to the foundations of health and medical research, Medlior explores topics relevant to clients and the world.

ISPOR EU 2023 in Copenhagen

ISPOR EU 2023 in Copenhagen

This year’s theme was “HEOR at the Nexus of Policy and Science” and, as with ISPOR in Boston in May, the real-world evidence (RWE) discussions largely focused on the use and acceptance of real-world data (RWD) in regulatory/reimbursement submissions.
MORSE and Medlior Join Forces

MORSE and Medlior Join Forces

We are thrilled to announce a groundbreaking collaboration between Medlior Health Outcomes Research and MORSE Consulting, two leaders in the Canadian pharmaceutical market access landscape.
Pathways to early access in oncology

Pathways to early access in oncology

The pressure on payers to offer patients timely access to life-saving oncology medicines has increased with the rapid development of innovative treatments. Balancing the urgency to provide access with the need for evidence-based decision-making from phase III trials presents a significant challenge to publicly funded systems worldwide.
Cardiology trends during the COVID-19 pandemic

Cardiology trends during the COVID-19 pandemic

The COVID-19 pandemic had profound impacts on healthcare systems and patients around the world. Systems faced unprecedented challenges including resource reallocation, overwhelmed hospitals, and disruptions in routine care. Retrospective studies are now assessing the long-term cumulative effects of the pandemic and associated public health measures.
Methods Matter: Misinterpreting Covariate Coefficients from Multivariable Models

Methods Matter: Misinterpreting Covariate Coefficients from Multivariable Models

The Table 2 fallacy suggests that even after carefully identifying confounding variables (covariates) to adjust for, it is common for researchers to mistakenly interpret each coefficient from an adjusted regression model as the total effect of the covariate, which is not the case.
Methods Matter: Adjusting for the Wrong Covariates Can Introduce Bias Instead of Correcting it

Methods Matter: Adjusting for the Wrong Covariates Can Introduce Bias Instead of Correcting it

Causal diagrams such as directed acyclic graphs (DAGs) can help in identifying a minimum set of confounding variables that need to be adjusted for. Arbitrarily dumping every available variable into a regression model can lead to biased estimates and incorrect conclusions about the effectiveness of a health intervention, its safety profile, and its downstream effects.
CADTH Symposium 2023: Is Canada Ready?

CADTH Symposium 2023: Is Canada Ready?

Medlior’s Founder and President Tara Cowling was delighted to attend the CADTH Symposium 2023 in Ottawa last week. On the heels of the ISPOR 2023 conference, CADTH also tackled some key issues surrounding the use of RWE to inform decision-making.
ISPOR 2023 in Boston

ISPOR 2023 in Boston

Hot-button items from the ISPOR 2023 conference included an emphasis on data quality, defining value, and caution with AI.
Treatment intensification and guideline LDL-C threshold achievement following acute myocardial infarction: Insights from a real-world evidence study

Treatment intensification and guideline LDL-C threshold achievement following acute myocardial infarction: Insights from a real-world evidence study

In a real-world Canadian population of high-risk patients with AMI, PCSK9i therapy in combination with other LLTs or alone was associated with better LDL-C reduction and higher proportions of patients meeting guideline thresholds; however, there was a longer time between the AMI event and PCSK9i treatments.
Accelerating access for rare diseases

Accelerating access for rare diseases

For many rare diseases, the drug development process is particularly challenging. A multi-pronged approach to overcoming these challenges is underway.
2022: A Year in Review

2022: A Year in Review

As we slowly emerged from our COVID caves of 2020-2021, this year brought great excitement to Medlior.  We helped industry bring life-changing innovations to market, and we increased our stakeholder collaboration.
Men’s Mental Health: A Silent Crisis

Men’s Mental Health: A Silent Crisis

November is men’s health awareness month – and some of the less-often-talked about health issues affecting men are about their mental health. The Canadian Mental Health Association is calling this a “silent crisis, a sleeper issue”.